Medical Benefit, Hospital Drugs Exempt From Detailed Cost, Coverage Reporting In Final Rule
The most detailed US reporting requirements regarding prescription drug costs and coverage will target medicines reimbursed under the retail pharmacy benefit.
You may also be interested in...
Lawsuit highlights the lack of transparency into pharmacy benefit manager activities and how their programs can influence drug pricing. A Senate hearing on PBMs held shows increasing momentum behind a Federal Trade Commission study on potential anti-competitive activity in the market sector.
Institute for Clinical and Economic Review analysis of whether payers are providing ‘fair access’ to fairly priced drugs was hampered by a lack of transparency among payers, leading to calls for reform.
Score of slimmed down Medicare negotiations in the Build Back Better legislation is $79bn, a far cry from the $456bn in savings projected from the draconian HR 3. But the bill’s overall impact on the deficit means that pharma might get a total reprieve – or go back on the chopping block.